InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,243.20
(
1.56%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.02%
)
Bitcoin
63,924.70
(
-0.87%
)
Post# of 251620
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119499
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 210039

Tuesday, 08/22/2017 4:24:30 PM

Tuesday, August 22, 2017 4:24:30 PM

Post# of 251620
RARE terminates GNE-myopathy program following phase-3 failure:

https://globenewswire.com/news-release/2017/08/22/1091258/0/en/Ultragenyx-Announces-Top-Line-Results-from-Phase-3-Study-of-Ace-ER-in-GNE-Myopathy.html

Ultragenyx Pharmaceutical…today announced that a Phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) did not achieve its primary endpoint of demonstrating a statistically significant difference in the upper extremity muscle strength composite score compared to placebo. The study also did not meet its key secondary endpoints… Ultragenyx plans to discontinue further clinical development of Ace-ER.

The stock is currently halted. No CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up